Preclinical Evaluation of the SARS-CoV-2 Mpro Inhibitor RAY1216
WuXi AppTec scientists contributed to a research article in the journal Nature Microbiology, which characterized a peptidomimetic inhibitor of the SARS-CoV-2 main protease (Mpro). In a human ACE2 transgenic mouse model, this inhibitor (designated RAY1216) exhibited antiviral activities against SARS-CoV-2 comparable to those of nirmatrelvir, but with improved pharmacokinetics.
Related Content
Varicella-zoster virus (VZV) is a highly contagious alpha-herpesvirus that infects more than 90% of people worldwide. The primary infection with...
VIEW RESOURCEHerpes simplex virus 1 and 2 (HSV-1 and HSV-2) are globally prevalent human pathogens associated with a wide range of...
VIEW RESOURCE